[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.250. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

September 2019 - April 2016

Decade

Year

Issue

December 2018, Vol 3, No. 12, Pages 1137-1256

In This Issue of JAMA Cardiology

Highlights

Abstract Full Text
free access
JAMA Cardiol. 2018;3(12):1137. doi:10.1001/jamacardio.2017.3396
Original Investigation

Association of Transcatheter Mitral Valve Repair With Quality of Life Outcomes at 30 Days and 1 Year: Analysis of the Transcatheter Valve Therapy Registry

Abstract Full Text
has audio
JAMA Cardiol. 2018;3(12):1151-1159. doi:10.1001/jamacardio.2018.3359

This cohort study uses data from the Transcatheter Valve Therapy Registry to examine health outcomes among patients undergoing transcatheter mitral valve repair for mitral regurgitation.

Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study

Abstract Full Text
JAMA Cardiol. 2018;3(12):1160-1166. doi:10.1001/jamacardio.2018.3811

This secondary analysis of a randomized clinical trial assesses if different biomarkers provide information about the risk for all-cause and cause-specific mortality after acute coronary syndrome.

Association of African Ancestry With Electrocardiographic Voltage and Concentric Left Ventricular Hypertrophy: The Dallas Heart Study

Abstract Full Text
JAMA Cardiol. 2018;3(12):1167-1173. doi:10.1001/jamacardio.2018.3804

This cohort study determines whether proportion of genetically determined African ancestry is associated with increased electrocardiographic voltage and concentric LV hypertrophy in black compared with white individuals.

Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II

Abstract Full Text
has audio
JAMA Cardiol. 2018;3(12):1174-1182. doi:10.1001/jamacardio.2018.3945

This cohort study uses data from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II to assess racial/ethnic differences in the use of oral anticoagulants by patients with atrial fibrillation.

Epigenetic Hallmarks of Fetal Early Atherosclerotic Lesions in Humans

Abstract Full Text
JAMA Cardiol. 2018;3(12):1184-1191. doi:10.1001/jamacardio.2018.3546

This autopsy study tests whether epigenetic signatures characterize early fetal atherogenesis associated with maternal hypercholesterolemia and provides a quantitative estimate of the contribution of maternal cholesterol level to fetal lesion size.

Influence of Cardiovascular Risk Communication Tools and Presentation Formats on Patient Perceptions and Preferences

Abstract Full Text
JAMA Cardiol. 2018;3(12):1192-1199. doi:10.1001/jamacardio.2018.3680

This randomized survey study explores how communication tools and presentation formats influence the perception of the severity of atherosclerotic cardiovascular disease risk as well as the potential willingness to take medication therapy among patients in the Patient and Provider Assessment of Lipid Management Registry.

Brief Report

Incidence of Atrial Fibrillation in Elite Athletes

Abstract Full Text
JAMA Cardiol. 2018;3(12):1200-1205. doi:10.1001/jamacardio.2018.3482

This study examines the incidence of atrial fibrillation in a cohort of elite athletes.

Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization

Abstract Full Text
open access has active quiz
JAMA Cardiol. 2018;3(12):1206-1210. doi:10.1001/jamacardio.2018.3539

This case-control study investigates whether if the normalized reciprocal of the plasma level of cardiac bridging integrator 1 protein differs in patients with heart failure with preserved ejection fraction, patients with risk factors for heart failure, and individuals with neither heart failure nor risk factors.

Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
JAMA Cardiol. 2018;3(12):1212-1217. doi:10.1001/jamacardio.2018.3798

This secondary analysis of the ASTRONOMER randomized clinical trial assesses whether plasma levels of lipoprotein(a) have a linear or a threshold association with rate of progression among patients with calcific aorta valve stenosis.

Association of Search Engine Queries for Chest Pain With Coronary Heart Disease Epidemiology

Abstract Full Text
JAMA Cardiol. 2018;3(12):1218-1221. doi:10.1001/jamacardio.2018.3459

This study investigates the correlation of online symptom search for chest pain using Google Trends with disease prevalence of coronary heart disease.

Association of Rankings With Cardiovascular Outcomes at Top-Ranked Hospitals vs Nonranked Hospitals in the United States

Abstract Full Text
JAMA Cardiol. 2018;3(12):1222-1225. doi:10.1001/jamacardio.2018.3951

This cross-sectional study examines 30-day risk-standardized mortality rates for coronary artery bypass grafting, acute myocardial infarction, and heart failure at top-ranked US News & World Report cardiology vs nonranked hospitals.

Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial

Abstract Full Text
JAMA Cardiol. 2018;3(12):1226-1231. doi:10.1001/jamacardio.2018.3957

This study calculates estimated 5-year number needed to treat values for the primary outcome of cardiovascular death or heart failure hospitalization with angiotensin receptor-neprilysin inhibitor therapy incremental to angiotensin-converting enzyme inhibitor in patients with heart failure with reduced ejection fraction (HFrEF) in the PARADIGM-HF trial.

Research Letter

Association of Age With Blood Pressure Across the Lifespan in Isolated Yanomami and Yekwana Villages

Abstract Full Text
JAMA Cardiol. 2018;3(12):1247-1249. doi:10.1001/jamacardio.2018.3676

This study examines cohorts of Yanomami and Yekwana individuals in Venezuela to assess how age affects blood pressure rise over time in isolated communities without Western exposure.

Characterizing High-Performing Articles by Altmetric Score in Major Cardiovascular Journals

Abstract Full Text
JAMA Cardiol. 2018;3(12):1249-1251. doi:10.1001/jamacardio.2018.3823

This study uses Altmetric scores to identify and describe the articles in 4 major cardiovascular journals that garnered the most digital attention in 2017.

Viewpoint

Implications of Medicare Coverage for Magnetic Resonance Imaging in Patients With Capped or Epicardial Leads

Abstract Full Text
JAMA Cardiol. 2018;3(12):1139-1140. doi:10.1001/jamacardio.2018.3820

This Viewpoint describes reasons why the Centers for Medicare and Medicaid Services should revisit a coverage decision affecting the ability of patients with pacemakers or implantable cardioverter-defibrillators to access magnetic resonance imaging.

From the Heart

The Illness We Carry

Abstract Full Text
JAMA Cardiol. 2018;3(12):1149-1150. doi:10.1001/jamacardio.2018.3139

This essay describes the author’s experience with Wolff-Parkinson-White syndrome and how it has translated to her medical career.

Editorial

Aortic Stenosis—50 Years of Discovery

Abstract Full Text
JAMA Cardiol. 2018;3(12):1141-1143. doi:10.1001/jamacardio.2018.3981

Electrocardiography Screening for Atrial Fibrillation: We Can Do Better

Abstract Full Text
JAMA Cardiol. 2018;3(12):1144-1145. doi:10.1001/jamacardio.2018.2200

Moving the Needle Toward a More Personalized Means of Patient Care

Abstract Full Text
JAMA Cardiol. 2018;3(12):1146-1148. doi:10.1001/jamacardio.2018.3900
Review

Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure: A Review

Abstract Full Text
JAMA Cardiol. 2018;3(12):1232-1243. doi:10.1001/jamacardio.2018.3789

This narrative review examines whether angiotensin II receptor blockade coupled with potentiation of key biological signaling pathways can favorably alter the course of heart failure with reduced ejection fraction.

JAMA Cardiology Clinical Challenge

Comatose 62-Year-Old Woman Following Cardiopulmonary Resuscitation

Abstract Full Text
has active quiz has multimedia
JAMA Cardiol. 2018;3(12):1244-1245. doi:10.1001/jamacardio.2018.2687

A 62-year-old woman unsuccessfully resuscitated after a cardiac arrest had elevated cardiac enzyme levels, ST-segment depression on the precordial leads, and wall motion abnormalities on TTE involving the midventricular wall without involvement of the basal of apical segments of the left ventricle. What would you do next?

Comment & Response

Role Models, Allies, and Diversity—Global Issues for Female Cardiology Trainees

Abstract Full Text
JAMA Cardiol. 2018;3(12):1251-1252. doi:10.1001/jamacardio.2018.3559

Role Models, Allies, and Diversity—Global Issues for Female Cardiology Trainees—Reply

Abstract Full Text
JAMA Cardiol. 2018;3(12):1252. doi:10.1001/jamacardio.2018.3570

The Cumulative Sex Wage Gap in Cardiology

Abstract Full Text
JAMA Cardiol. 2018;3(12):1252-1253. doi:10.1001/jamacardio.2018.3795

Errors in Programming and Coding Affecting Cohorts Included in the Study Deriving and Validating the PROMISE Minimal-Risk Tool

Abstract Full Text
JAMA Cardiol. 2018;3(12):1253-1254. doi:10.1001/jamacardio.2018.3897

High-Density Lipoprotein–Targeted Therapies—Not Dead Yet

Abstract Full Text
JAMA Cardiol. 2018;3(12):1254-1255. doi:10.1001/jamacardio.2018.3962

High-Density Lipoprotein–Targeted Therapies—Not Dead Yet—Reply

Abstract Full Text
JAMA Cardiol. 2018;3(12):1255-1256. doi:10.1001/jamacardio.2018.3973
Editor's Note

Cardiovascular Disease Disparities: The Gap Remains

Abstract Full Text
JAMA Cardiol. 2018;3(12):1183. doi:10.1001/jamacardio.2018.4040

The Urgent Need for Biomarkers Beyond B-Type Natriuretic Peptide for the Diagnosis and Management of Heart Failure With Preserved Ejection Fraction

Abstract Full Text
JAMA Cardiol. 2018;3(12):1211. doi:10.1001/jamacardio.2018.3702
Correction

Programming and Coding Errors in a Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
free access
JAMA Cardiol. 2018;3(12):1256. doi:10.1001/jamacardio.2018.3916
JAMA Cardiology Masthead

JAMA Cardiology

Abstract Full Text
free access
JAMA Cardiol. 2018;3(12):1138. doi:10.1001/jamacardio.2017.3397
×